Teva Pharmaceuticals

We’re a leading innovative biopharmaceutical company, enabled by a world-class generics business. Guidelines:

[Teva Pharmaceuticals @TevaUSA]

BREAKING: Teva receives FDA approval for a new biosimilar treatment to help prevent skeletal-related events in people with certain cancers or bone metastases from solid tumors, and to treat hypercalcemia of malignancy: https://t.co/EYHMo1Chi2 $TEVA #PivotToGrowth

[Teva Pharmaceuticals @TevaUSA]

@DAbitty Thank you for your message. Please contact our Customer Service team for questions or issues regarding our medicines in the US:Tel: 888-TEVA-USA (888-838-2872) or email: [email protected]

[Teva Pharmaceuticals @TevaUSA]

At #PsychCongress2026, Teva presents new studies within our innovative medicines portfolio, covering the latest research and real-world evidence in schizophrenia, bipolar I disorder and tardive dyskinesia.

Read the press releases here: https://t.co/ur7BKWrzRA

[Teva Pharmaceuticals @TevaUSA]

Today, we are announcing the launch of https://t.co/qqxXlW23dk, a resource built to provide healthcare professionals with practical guidance and insights on utilizing long-acting injectables (LAIs) for #schizophrenia treatment.

Learn more: https://t.co/OUWoQfLyQj

[NYSE 🏛 @NYSE]

The NYSE welcomes @TevaUSA to celebrate its first day of trading ordinary shares! $TEVA https://t.co/3bPqhmN6fU

[Teva Pharmaceuticals @TevaUSA]

@MonsuratOmolar3 Thanks for letting us know! Please report any product concerns to our US Quality Department at 888-838-2872 or [email protected].

[Teva Pharmaceuticals @TevaUSA]

Exciting #news: Teva achieves Investment Grade from all three leading credit rating agencies, as @SPGlobalRatings joins @moodysratings and @FitchRatings in upgrading Teva’s rating, recognizing the progress we have made to strengthen our financial profile and execute our Pivot to Growth strategy.
Learn more: https://t.co/x3XiVsRDzq

[Teva Pharmaceuticals @TevaUSA]

@und3rth3nail appropriate representative in Teva will respond to you: https://t.co/6MLeZSmrpC 2/2

[Teva Pharmaceuticals @TevaUSA]

@und3rth3nail Thank you for your message. To report an adverse event associated with a Teva product, please email [email protected] with your contact details and the name of the product, or visit our company website where you can submit your information and any questions, and an 1/2

[Teva Pharmaceuticals @TevaUSA]

#Breaking: Teva announces positive topline results from phase 2a study in celiac disease for its anti-il-15 antibody, further validating its pipeline-in-a-product potential.
Join the webcast today at 8:00 am ET: https://t.co/MzZNWxg642
Read the press release: https://t.co/JYPz0WX9gf

[Teva Pharmaceuticals @TevaUSA]

The @US_FDA has accepted Teva’s NDA and granted Priority Review for a potential new treatment option for pediatric patients living with #TouretteSyndrome.

Learn more here: https://t.co/wR6XdLb0ve

#PivotToGrowth $Teva

[Teva Pharmaceuticals @TevaUSA]

@highafagain Thanks for letting us know! Please report any product concerns to our US Quality Department at 888-838-2872 or [email protected].

[Squawk on the Street @SquawkStreet]

"It's a pipeline that not only meets unmet medical need – we believe it has a high probability of being successful."

@TevaUSA CEO Richard Francis explains why the company's developing its own drugs instead of sticking strictly with generics:
https://t.co/v3X6LlSk9k

[Teva Pharmaceuticals @TevaUSA]

Our Q2 2026 earnings call is starting in 30 minutes. Join CEO Richard Francis live to hear about Teva's business performance and plans ahead.
https://t.co/u42km2SaYP
Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release.
#QuarterlyResults #Earnings $Teva

[Teva Pharmaceuticals @TevaUSA]

We are reporting our Q2 2026 financial results, as we continue our transformation into a leading biopharma company
https://t.co/KFrXj1Y2kO
Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release.
#QuarterlyResults #Earnings $Teva

[Teva Pharmaceuticals @TevaUSA]

Hi sheisenseii,
Thank you for bringing this to our attention, and we're sorry for the frustration this has caused.
We recently moved to an enhanced careers platform and are in the final stages of retiring features from our previous system. As part of this transition, all job alert subscriptions created on the legacy platform will be disabled in the coming days.
Once this update is complete, you should no longer receive job alert emails associated with your previous subscription.
Thank you for your patience as we make this change. Our new careers experience is designed to be more seamless, intuitive, and easier to navigate for candidates.
We'd still love to stay connected and welcome you to explore future opportunities with us should the right one come along!

[Teva Pharmaceuticals @TevaUSA]

Tune in to our Q2 2026 earnings call with CEO Richard Francis and the Teva leadership team on Wednesday, July 29.
Save the date: https://t.co/cGPo74hyLT

#QuarterlyResults #Q2Results #Earnings $Teva
Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release.

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

🆕Results from RELIEVE UCCD - efficacy and safety of duvakitug in patients with Crohn's disease or ulcerative colitis

UC - https://t.co/HvZYiTj09f

CD - https://t.co/snSFwICeZ7

#GITwitter #MedTwitter

[Teva Pharmaceuticals @TevaUSA]

An exciting moment: @LancetGastroHep published peer-reviewed analyses from our Phase 2b study for an investigational treatment for #UlcerativeColitis and #CrohnsDisease.
Read more:
https://t.co/5VSrtgLTe9
https://t.co/qgFOYJdUuq

[Teva Pharmaceuticals @TevaUSA]

@ewheeler1976 Thank you for your message. Please contact our Customer Service team for questions or issues regarding our medicines in the US:Tel: 888-TEVA-USA (888-838-2872) or email: [email protected]